| September 22, 2026 |
Opinion — Zetagen Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for primary and metastatic breast cancer, today announced preliminary topline results from its Phase 2a clinical study evaluating ZetaMet™ (Zeta BC 003) in subjects with metastatic breast cancer (MBC) with lytic bone lesions. The post The Future is About Personalised Medicine, Targeted Therapies, Immunotherapy, and Increasingly Precise Drug Delivery Working Together appeared first on Zetagen . |
